It was learned that, according to a disclosure by the Hong Kong Stock Exchange on January 30, WiseTek Med Ltd. has submitted a listing application for the Main Board. China Construction Bank International (CCB International) is acting as the sole sponsor.

The prospectus reveals that WiseTek Med is a platform-based medical device company. Leveraging its innovative visualization and minimally invasive medical devices, the company holds a leading position in the field of single-use urological endoscopes.

The company operates in both Silicon Valley and China, focusing on the research, development, and commercialization of single-use endoscope systems.

WiseTek Med is one of the very few companies globally to have successfully achieved vertical integration of the supply chain for single-use endoscopes. This integration spans the entire process, from the independent R&D and manufacturing of core optoelectronic components and precision parts to the final assembly of complete systems.

Through its proprietary brand portfolio—which includes OTU (ONETU®), the OTU co-brand developed in partnership with leading medical technology companies, and WiScope®—the company has developed a comprehensive product portfolio covering urology, hepatobiliary surgery, respiratory, ENT, gastroenterology, and gynecology.